Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia

Blood

Volumn 126, Issue 16, 2015, Pages 1921-1924

  Rossi, Davide ^a   Terzi Di Bergamo, Lodovico ^a   De Paoli, Lorenzo ^a   Cerri, Michaela ^a   Ghilardi, Guido ^a   Chiarenza, Annalisa ^b   Bulian, Pietro ^c   Visco, Carlo ^d   Mauro, Francesca R ^e   Morabito, Fortunato ^f   Cortelezzi, Agostino ^g   Zaja, Francesco ^h   Forconi, Francesco ^i,j   Laurenti, Luca ^k   Del Giudice, Ilaria ^e   Gentile, Massimo ^f   Vincelli, Iolanda ^l   Motta, Marina ^m   Coscia, Marta ⁿ   Rigolin, Gian Matteo ^o   Tedeschi, Alessandra ^p   Neri, Antonino ^g   Marasca, Roberto ^q   Perbellini, Omar ^r   Moreno, Carol ^s   Del Poeta, Giovanni ^t   Massaia, Massimo ^u   Zinzani, Pier Luigi ^v   Montillo, Marco ^p   Cuneo, Antonio ^o   Gattei, Valter ^c   Foà, Robin ^e   Gaidano, Gianluca ^a   more..

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d SAN BORTOLO HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f Civic Hospital of Cosenza   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

ⁱ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^j UNIVERSITY OF SIENA   (Italy)

^k CATHOLIC UNIVERSITY   (Italy)

^l Hospital of Reggio Calabria   (Italy)

^m SPEDALI CIVILI   (Italy)

ⁿ CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^o UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^p OSPEDALE NIGUARDA CA GRANDA   (Italy)

^q UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^r UNIVERSITY OF VERONA   (Italy)

^s HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^t UNIVERSITY OF ROME TOR VERGATA   (Italy)

^u UNIVERSITY OF TURIN   (Italy)

^v UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB; ANTINEOPLASTIC AGENT; VIDARABINE;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIFE EXPECTANCY; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; ANALOGS AND DERIVATIVES; CHROMOSOME 11; CHROMOSOME 17; CHROMOSOME DELETION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SMITH MAGENIS SYNDROME; SURVIVAL RATE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 17; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; RITUXIMAB; SMITH-MAGENIS SYNDROME; SURVIVAL RATE; VIDARABINE;

EID: 84944248903     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-05-647925     Document Type: Review

References (25)

1. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005; 23(18): 4079-4088.
2. Hallek M, Fischer K, Fingerle-Rowson G, et al; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet. 2010; 376(9747): 1164-1174.
3. Lepretre S, Aurran T, Mahé B, et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012; 119(22): 5104-5110.
4. Tam CS, O'Brien S, Wierda W, et al. Long-Term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008; 112(4): 975-980.
5. Lin KI, Tam CS, Keating MJ, et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood. 2009; 113(14): 3168-3171.
6. Fink AM, Böttcher S, Ritgen M, et al. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. Leukemia. 2013; 27(9): 1949-1952.
7. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: Results from the CLL8 trial. Blood. 2014; 123(21): 3247-3254.
8. Tam CS, O'Brien S, Plunkett W, et al. Long-Term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014; 124(20): 3059-3064.
9. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1): 32-42.
10. Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: A single-Arm, phase 2 study. Lancet Oncol. 2014; 15(10): 1090-1099.
11. Byrd JC, Brown JR, O'Brien S, et al; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371(3): 213-223.
12. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370(11): 997-1007.
13. O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014; 15(1): 48-58.
14. Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: A phase 2, single-Arm trial. Lancet Oncol. 2015; 16(2): 169-176.
15. Shanafelt TD, Borah BJ, Finnes HD, et al. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J Oncol Pract. 2015; 11(3): 252-258.
16. Foà R, Guarini A. A mechanism-driven treatment for chronic lymphocytic leukemia? N Engl J Med. 2013; 369(1): 85-87.
17. Foà R. Changes in the treatment landscape for chronic lymphoid leukemia. N Engl J Med. 2014; 371(3): 273-274.
18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006; 100(2): 229-235.
19. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood. 1996; 87(12): 4990-4997.
20. Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12): 5446-5456.
21. Strati P, Keating MJ, O'Brien SM, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014; 123(24): 3727-3732.
22. Böttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012; 30(9): 980-988.
23. Hisada M, Biggar RJ, Greene MH, Fraumeni JF Jr, Travis LB. Solid tumors after chronic lymphocytic leukemia. Blood. 2001; 98(6): 1979-1981.
24. Benjamini O, Jain P, Trinh L, et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: Distribution and clinical outcomes. Leuk Lymphoma. 2015; 56(6): 1643-1650.
25. Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014; 124(1): 49-62.